A lot to unpack. Interesting biotech company, used a lot in academia, have a well established long term clientèle as they provide the kits for the machines which run the anaylsis ect. Around for 20+ years, A new well respected CFO recently announced. They over spent in the last few years trying to expand, also being sued for patent infringement by 10x geomic/harvard…which is a main cause for the crash, thought its looking less likely they will loss, due to anti-trust counter sue. Even if they loss, it is only the new platform that will be removed and the other long established will contiune. Strong fear of bankruptcy and their recent conference call wasnt particularly inspiring. Negative cash flow, 121m MC, 1 year left on the books before bankruptcy.
Thoughts?
Leave a Reply